ReviewCurrent cardiology reports2024
Transcatheter Therapy for the Tricuspid Valve: A Focused Review of Edge-to-Edge Repair and Orthotopic Valve Replacement.
Review in Current cardiology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Tricuspid valve disease: updates on diagnostic imaging and intervention.Nature reviews. Cardiology · 2026Review
- Review
- Three decades evolution of the lifetime management approach to tricuspid valve disease: a multidisciplinary European perspective from a high-volume heart valve center.Annals of cardiothoracic surgery · 2026Article
- Surgical and Transcatheter Tricuspid Valve Interventions: An Electrophysiology-Focused Review.Journal of cardiovascular development and disease · 2026Review
- Focus on tricuspid valve-the European perspective.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Carcinoid Heart Disease: The Role of Echocardiography in Raising the First Suspicion.Journal of clinical medicine · 2026Review
- Clinical outcomes of tricuspid transcatheter edge-to-edge repair in patients with tricuspid regurgitation.Frontiers in medicine · 2026Article
- Management of Tricuspid Valve Regurgitation Consensus Recommendations.Heart views : the official journal of the Gulf Heart Association · 2026Review
- Choosing Between Tricuspid Repair or Replacement: Decision Algorithms.Structural heart : the journal of the Heart Team · 2025Review
- Determinants of recovery from right ventricular dysfunction after transcatheter edge-to-edge tricuspid valve repair.Journal of cardiovascular medicine (Hagerstown, Md.) · 2025Article
- Real-World Clinical Outcomes and Health Care Utilization in Patients With Severe Tricuspid Regurgitation.Structural heart : the journal of the Heart Team · 2025Article
- Atrial Functional Tricuspid Regurgitation: A Comprehensive Review of Pathophysiology, Diagnosis, and Management Strategies.Reviews in cardiovascular medicine · 2024Review
- Key Imaging Factors for Transcatheter Management of Tricuspid Regurgitation: Device and Patient Selection.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPatients with severe tricuspid regurgitation (TR) are at risk for significant morbidity and mortality. Transcatheter tricuspid valve interventions (TTVI) may offer patients less invasive treatment alternatives to surgery. This review evaluates the most common class of device currently used worldwide to treat TR, tricuspid transcatheter edge-to-edge repair (T-TEER) and orthotopic transcatheter tricuspid valve replacement (TTVR), both of which are now approved in the USA and Europe. RECENT
findingsThe first pivotal randomized clinical trial, TRILUMINATE, demonstrated that T-TEER can safely reduce TR and is associated with improved health status outcomes. However, results of this trial have raised questions about whether this device can provide sufficient TR reduction to impact clinical outcomes. Orthotopic TTVR has recently gained attention with initial data suggesting near-complete TR elimination. The current review examines the technical features and anatomic limitations of the most commonly used devices for T-TEER and orthotopic TTVR, discusses the current clinical data for these devices, and offers a theoretical construct for device selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.